Photo: Logo of Amoy Diagnostics Co., Ltd.
BEIJING, June 30 (Xinhua) -- Amoy Diagnostics Co., Ltd. (300685.SZ) announced on Tuesday that its lung cancer detection product has been approved by the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan, meaning that the product can be sold in the Japanese market.
The product called AmoyDx Pan lung cancer PCR panel is developed independently by the listed company, based on the polymerase chain reaction (PCR) technology.
This is another companion diagnostic product approved in Japan after its ROS1 companion diagnostic product for lung cancer was approved in 2017, according to the listed company.
The approval of the product by the PMDA marks that the company has consolidated its strength in the Japanese companion diagnostics market and will help enhance its competitiveness, said its filing to the stock exchange.
Amoy Diagnostics Co., Ltd., headquartered in Xiamen, southeast China's Fujian Province, is engaged in the research and development, production, sales and service of tumor precision medical diagnostic products. (Edited by Hu Pingchao, Wang Siyi with Xinhua Silk Road, hupingchao@xinhua.org)
A single purchase
